Skip to main content
SpringerLink
Log in

Escitalopram: refining a commonly prescribed SSRI

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig

Notes

  1. The use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17 (5): 343–62.

    Article  PubMed  CAS  Google Scholar 

  2. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001 Sep 1; 50 (5): 345–50.

    Article  PubMed  CAS  Google Scholar 

  3. Mendlewicz J. Predicting response: serotonin reuptake inhibition. Int Clin Psychopharmacol 1999 May; 14 Suppl. 1: S17–20

    Article  PubMed  Google Scholar 

  4. British National Formulary. No. 46. London: The Pharmaceutical Press, 2003 Sep

  5. Tan JY, Levin GM. RS-citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 1999 Jun; 19: 675–89.

    Article  PubMed  CAS  Google Scholar 

  6. Forest Laboratories Inc. Escitalopram (Lexapro) prescribing information [online]. Available from URL: http://www.lexapro.com [Accessed 2003 Oct 24]

  7. Lundbeck A/S. Escitalopram prescribing information [online]. Available from URL: http://www.cipralex.com [Accessed 2003 Oct 24]

  8. Forest Laboratories Inc. Lexapro receives FDA approvable letter for the treatment of generalised anxiety disorder (GAD) [media release]. 2003 Sep 29

  9. Stórustovu S, Sánchez C, Pörzgen, et al. (R)-Citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter [abstract no. P.1.073]. Eur Neuropsychopharmacol 2003; 13 Suppl. 4: S205.

    Article  Google Scholar 

  10. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002 Apr; 63 (4): 331–6.

    Article  PubMed  CAS  Google Scholar 

  11. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002 May; 17(3): 95–102

    Article  PubMed  CAS  Google Scholar 

  12. Lepola U, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18 (4): 211–7.

    Article  PubMed  Google Scholar 

  13. Ninan PT, Ventura D, Wang J. Escitalopram is effective and well tolerated in the treatment of severe depression [poster no. NR486]. 156th Annual Meeting of the American Psychiatric Association, 2003 May 17–22; San Francisco

  14. Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Int J Psych Clin Prac 2002; 6: 243–4

    Google Scholar 

  15. Montgomery SA, Huusom AKT, Bothmer J. Escitalopram is a new and highly efficacious SSRI in the treatment of major depressive disorder [abstract no. P. 1.206]. J Eur Neuropsychopharmacol 2002 Oct; 12 Suppl. 3: S224

    Google Scholar 

  16. Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder [abstract no. P1.207]. Eur Neuropsychopharmacol 2003; 13 Suppl. 4: S262.

    Google Scholar 

  17. Rapaport MH, Bose A, Zheng H. Escitalopram prevents relapse of depressive episodes. Eur Psychiatry 2002 May; 17 Suppl. 1: 97

    Article  Google Scholar 

  18. Wade A, Despiegel N, Reines E. Depression in primary care patients: improvement during long-term escitalopram treatment [abstract no. P.1.156]. J Eur Neuropsychopharmacol 2002 Oct; 12 Suppl. 3: S224

    Google Scholar 

  19. Stahl S, Gergel I, Li D. Escitalopram in the treatment of panic disorder. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S217.

    Google Scholar 

  20. Lader M, Stender K, Bürger V, et al. Fixed doses of escitalopram and paroxetine for the treatment of social anxiety (SAD) [abstract no. P.3.026]. Eur Neuropsychopharmacol 2003; 13 Suppl. 4: S364.

    Article  Google Scholar 

  21. Montgomery SA, Dürr-Pal N, Loft H, et al. Relapse prevention by escitalopram treatment of patients with social anxiety disorder (SAD) [abstract no. P3.025]. Eur Neuropsychopharmacol 2003; 13 Suppl. 4: S364.

    Article  Google Scholar 

  22. Goodman WK, Bose A, Wang Q. Escitalopram 10 mg/day is effective in the treatment of generalised anxiety disorder [poster no. NR806]. 156th Annual Meeting of the American Psychiatric Association, 2003 May 17–22; San Francisco

  23. Davidson JRT, Bose A, Zheng H. Escitalopram in the treatment of generalised anxiety disorder: a double-blind, placebo-controlled, flexible dose study [poster no. NR821]. 156th Annual Meeting of the American Psychiatric Association, 2003 May 17–22; San Francisco

  24. Davidson JRT, Bose A, Wang Q. Escitalopram in the long-term treatment of generalized anxiety disorder [poster no. P.3.315]. 16th Congress of the European College of Neuropsychopharmacology; 2003 Sep 20–24; Prague

  25. François C, Sintonen H, Toumi M, et al. Introduction of escitalopram a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of budgetary impact. J Drug Assess 2002; 5: 221–37

    Google Scholar 

  26. François C, Henrikkson F, Toumi M, et al. A Swedish pharmacoeconomic evaluation of escitalopram, a new SSRI: comparison of cost-effectiveness between escitalopram, RS-citalopram, fluoxetine and venlafaxine [abstract]. Value Health 2002 Jun; 5: 230.

    Article  Google Scholar 

  27. Montgomery SA, Fernandez J, François C. Treatment of depression: escitalopram has similar efficacy but lower costs compared to venlafaxine XR [abstract no. PMH42]. Value Health 2003; 6 (3): 358.

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Escitalopram: refining a commonly prescribed SSRI. Drugs Ther. Perspect 19, 1–4 (2003). https://doi.org/10.2165/00042310-200319120-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319120-00001

Keywords

Search

Navigation